SCHEMBL7130668

SCHEMBL7130668

c1ccc(-c2cnc(Nc3cccc(-n4ccnc4)c3)c3ccccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.53
PDGFRB P09619 1/20 0.53
BCR P11274 1/20 0.53
SRC P12931 1/20 0.53
PDGFRA P16234 1/20 0.53
PRKCA P17252 1/20 0.53
PRKCD Q05655 1/20 0.53
CYP3A4 P08684 4/20 0.44
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
SYK P43405 4/20 0.44
TSHR P16473 2/20 0.44
MEN1 O00255 1/20 0.44
ALOX15 P16050 1/20 0.44
KMT2A Q03164 1/20 0.44
IDO1 P14902 1/20 0.42
CD38 P28907 1/20 0.41
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128731 0.90 ABL1 (0.53) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7122153 0.81 ABL1 (0.48) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7117333 0.80 ABL1 (0.54) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL28512889 0.80 ABL1 (0.53) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL31440677 0.80 ABL1 (0.53) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL21362368 0.79 CYP3A4 (0.62) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7124011 0.78 ABL1 (0.49) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7125048 0.77 ABL1 (0.48) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7119129 0.76 KDR (0.59) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7121990 0.76 EGFR (0.51) ABL1PDGFRBBCRSRCPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 ABL1 212/4885PDGFRB 2353/4885BCR 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.